Idecabtagene vicleucel

Multiple myeloma

Unassigned

New Medicines

Relapsed or refractory multiple myeloma in adults who have received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody

Information

Advanced therapy medicinal product (ATMP)
Bluebird Bio
Bluebird Bio

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Anti-BCMA chimeric antigen receptor (CAR)-T cell therapy.
MM is the second most common haematological cancer, responsible for 15-20% of deaths from haematological cancer and about 2% of all deaths from cancer. Incidence in Europe is 4.5-6.0 per 100,000 per year with a mortality rate of 4.1 per 100,000 per year [3].
Relapsed or refractory multiple myeloma in adults who have received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody
Intravenous infusion

Trial or other data

Dec 19 · No UK trial sites [8]

Evidence based evaluations

Relapsed or refractory multiple myeloma (MM) in adults who have received at least 2 but no greater than 4 prior MM regimens

Information

Advanced therapy medicinal product (ATMP)
Bluebird Bio
Bluebird Bio

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Anti-BCMA chimeric antigen receptor (CAR)-T cell therapy. Given as a single infusion.
MM is the second most common haematological cancer, responsible for 15-20% of deaths from haematological cancer and about 2% of all deaths from cancer. Incidence in Europe is 4.5-6.0 per 100,000 per year with a mortality rate of 4.1 per 100,000 per year [1].
Relapsed or refractory multiple myeloma (MM) in adults who have received at least 2 but no greater than 4 prior MM regimens
Intravenous infusion

Trial or other data

Dec 19 · No UK trial sites [5]